Full View

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial

RW Ross, MD Galsky, P Febbo, M Barry, JP Richie… - Cancer, 2012 - Wiley Online Library
BACKGROUND: Treatment of high‐risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …
被引用次数：67 相关文章

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

RW Ross, MD Galsky, P Febbo, M Barry, JP Richie… - Cancer, 2012 - europepmc.org
Background Treatment of high-risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …

[引用][C] Phase 2 Study of Neoadjuvant Docetaxel Plus Bevacizumab in Patients With High-Risk Localized Prostate Cancer: A Prostate Cancer Clinical Trials …

RW ROSS, MD GALSKY, CM TEMPANY… - Cancer, 2012 - pascal-francis.inist.fr
Phase 2 Study of Neoadjuvant Docetaxel Plus Bevacizumab in Patients With High-Risk
Localized Prostate Cancer: A Prostate Cancer Clinical Trials Consortium Trial CNRS Inist …
[HTML] nih.gov

[HTML][HTML] Phase II Study of Neoadjuvant Chemotherapy with Docetaxel and Bevacizumab in Patients with High-Risk Localized Prostate Cancer: A Prostate Cancer …

RW Ross, MD Galsky, P Febbo, M Barry, JP Richie… - Cancer, 2012 - ncbi.nlm.nih.gov
Background Treatment of high-risk localized prostate cancer remains inadequate. We
performed a phase II multicenter trial of neoadjuvant docetaxel plus bevacizumab prior to …

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer

RW Ross, MD Galsky, P Febbo, M Barry, JP Richie… - Cancer, 2012 - infona.pl
BACKGROUND: Treatment of high‐risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer.

RW Ross, MD Galsky, P Febbo, M Barry… - Cancer …, 2012 - search.ebscohost.com
BACKGROUND: Treatment of high-risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial

RW Ross, MD Galsky, P Febbo, M Barry… - Cancer, 2012 - pubmed.ncbi.nlm.nih.gov
Background Treatment of high-risk localized prostate cancer remains inadequate. The
authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab …

[引用][C] Phase 2 Study of Neoadjuvant Docetaxel Plus Bevacizumab in Patients With High-Risk Localized Prostate Cancer: A Prostate Cancer Clinical Trials …

RW ROSS, MD GALSKY, P FEBBO, M BARRY… - Cancer, 2012 - Wiley-Blackwell